Accelerating clinical trials with AI

It's about time.

Unlearn’s First Ever Webinar Series, Powering Clinical Research with AI, is available On-Demand

Join us at AD/PD 2021

Unlearn will present novel, AI-driven approaches to enabling smaller, more efficient Alzheimer’s clinical trials

Accelerating clinical trials with AI

It's about time.

A new paradigm for faster trials providing rigorous clinical evidence with fewer subjects.

The Problem

Enrollment challenges, timeline delays, and high failure rates burden clinical trials. AI can change that.

What we do

Unlearn is the only company to create digital twins to populate Intelligent Control Arms in clinical studies.

Why it's unique

While others leverage existing data, Unlearn generates a new type of data, for any type of patient.

The Problem

Enrollment challenges and timeline delays plague clinical trials.

THe old way

External controls can help solve these problems, but are typically unreliable.

the new way

TwinRCTs™ generate reliable evidence in a fraction of the time.

How it works

TwinRCTs™ combine AI, Digital Twins, and novel statistical methods to enable smaller, more efficient trials.

Make trials more patient-centric

Clinical trials with smaller control groups are more attractive to patients.

Shorten enrollment timelines

TwinRCTs™ reach enrollment targets faster because they require fewer patients.

Increase power and confidence

TwinRCTs™ provide reliable evidence suitable for pivotal clinical trials.

Machine learning for comprehensive forecasting of Alzheimer's Disease progression

We have shown that generative models capable of sampling conditional probability distributions over a diverse array of clinical variables can accurately model the...


Research, Perspectives, and Insights


European Medicines Agency Qualifies Unlearn’s AI-powered Method for Running Smaller, Faster Clinical Trials


Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™


Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials